<DOC>
	<DOCNO>NCT00438815</DOCNO>
	<brief_summary>The study objective evaluate safety efficacy repeat use C1INH-nf treatment acute HAE attack .</brief_summary>
	<brief_title>Open-Label C1 Esterase Inhibitor ( C1INH-nf ) Treatment Acute Hereditary Angioedema ( HAE ) Attacks</brief_title>
	<detailed_description>A total 113 subject enrol study . One-hundred-one ( 101 ) subject receive C1INH-nf treatment 1 HAE attack analyze efficacy . The study design also allow short-term prophylaxis C1INH-nf prior emergency non-cosmetic surgical dental procedure , additional 12 subject receive C1INH-nf purpose . All 113 subject expose C1INH-nf analyzed safety .</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>This study open subject : Completed participation LEVP20051/A ( NCT00289211 ) participate LEVP20051/B ( NCT01005888 ) , time 3day telephone followup Completed participation LEVP20051/B time final prophylactic therapy Part B Were enrol randomize LEVP20051/A Part A close Were exclude LEVP20051 follow reason : Pregnancy lactation Age le 6 year Narcotic addiction Presence antiC1INH autoantibody Were enrol LEVP20051 enrollment LEVP20051 close , follow circumstance : Had diagnosis HAE : evidence low C4 level plus either low C1INH antigenic level low C1INH functional level , Had know HAEcausing C1INH mutation , Had diagnosis HAE base strong family history HAE determine principal investigator History allergic reaction C1INH blood product Participated investigational drug study within past 30 day Received blood blood product past 60 day C1INHnf</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Hereditary angioedema</keyword>
	<keyword>C1 esterase inhibitor ( human )</keyword>
</DOC>